Targetting Ophthalmic Therapeutics

Retinset Icon logo


What is Diabetic Retinopathy (DR)?

DR is a microvascular and neurodegenerative complication of diabetes

  • Leading cause of preventable blindness among working-aged adults.
  • Responsible for 12% of all cases of blindness in Europe and the USA.
  • Affects 1 out of 3 persons with diabetes mellitus (DM).
  • 387M people with DM in the world, estimated to increase to 592M people in 2035.
  • 145M people worldwide and from 22 to 30M of Europeans suffer from DR.
  • 3%-10% of DR patients will have diabetic macular oedema and 30% of them will have visual impairment.
Normal retina imageArrowNormal retina landscape
Diabetic retinopathy imageArrowDiabetic retinopathy landscape

Formulation Platform

  • Development of innovative formulation strategies for ophthalmic drug delivery.
    Science 1 imgScience 2 imgScience 3 img
  • eco-Friendly Formulations.
  • Patent protected.